Extended Data Table 3 Additional safety and tolerability of FX-909 - Time-To-Onset of first grade ≥3 TRAE in total population - All (N = 56 patients)

From: A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial